Compare Trump Media and Technology Group Corp (DJT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Trump Media and Technology Group Corp trades at $8.32 (market cap $2.48B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 54.1× Trump Media and Technology Group Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| DJT | VRTX | |
|---|---|---|
Market Cap | $2.48B | $134.25B |
Sector | Media | Health |
52-Week High | $18.50 | $529.65 |
52-Week Low | $7.06 | $376.62 |
Enterprise Value | $2.54B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT stock trades at $8.38, down 10.81% in the last 24 hours, reflecting a bearish technical signal. The company reported Q2 2026 revenue of $1.67 million, up 89% year-over-year, but net losses widened to $238.1 million due to digital asset declines. The price-to-sales ratio of 547.62 indicates an extremely high valuation relative to minimal revenue, while negative profitability metrics and substantial cash burn persist.
The outlook remains highly speculative with significant risks from unsustainable losses and volatile digital asset holdings. Investment appeal is limited to high-risk tolerance given the lack of profitability and bearish analyst sentiment. Key catalysts include future revenue growth from new products like the Truth API, but current fundamentals do not support the valuation.
Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.
Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
